Short answer
Humacyte, Inc. (HUMA) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $495,000 (down 4.3% year over year) with net income of −$18M.
Q1 2026 key financials · XBRL
- Revenue
- $495,000
- −4.3% YoY
- Net income
- −$18M
- −145.0% YoY
- Operating margin
- -5845.5%
- EPS (diluted)
- −$0.09
- −132.1% YoY
Source: XBRL data from the Humacyte, Inc. (HUMA) Q1 2026 10-Q on SEC EDGAR. USD.
Humacyte, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $495K, down 4% YoY from $517K, with Symvess product revenue $493K vs $147K
- Operating loss $28.9M vs $23.2M; operating margin -5,846.5% vs -4,484.3% YoY
- Cost of goods sold $2.0M vs $0.1M, including a $1.6M inventory reserve
- Operating cash outflow $25.1M vs $28.6M; cash and equivalents $48.5M plus restricted cash $0.4M
- $18.3M net proceeds from March registered direct offering; going-concern doubt and expected future losses തുടര
Risk Factors
- New cost-reduction risk triggered by May 2026 workforce plan affecting approximately 45 employees
- Workforce cuts could disrupt operations, with $0.8 million severance charges and $14.3 million expected 2026 savings
- Nasdaq delisting risk triggered by bid price below $1.00 for 30 consecutive business days
- Compliance deadline November 2, 2026, requiring $1.00 closing bid for 10 consecutive business days
- Delisting could reduce liquidity and hinder capital raising for ongoing operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Humacyte, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.